dabigatran

This page shows the latest dabigatran news and features for those working in and with pharma, biotech and healthcare.

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

Ingelheim’s thrombin inhibitor Pradaxa (dabigatran).

CHMP backs Lynparza in breast cancer, Dupixent in asthma

So far, Boehringer Ingelheim’s rival NOAC Pradaxa (dabigatran) - which works by inhibiting thrombin - is the only NOAC on the market with a reversal agent available.
Bad news for Portola as CHMP considers Factor Xa drugs

In the meantime, Boehringer Ingelheim’s rival NOAC Pradaxa (dabigatran) - which works by inhibiting thrombin - remains the only new anticoagulant on the market with a reversal agent available.
Xarelto no better than aspirin in secondary stroke study

For years it led the market among NOAC drugs, keeping ahead of Pfizer and Bristol-Myers Squibb’s Eliquis (apixaban) and with Boehringer Ingelheim’s Pradaxa (dabigatran) and Daiichi Sankyo’s
Xarelto beats aspirin for recurrent blood clots

rival NOAC Eliquis (apixaban) from Pfizer and Bristol-Myers Squibb (BMS) with 42.5%, well ahead of third place Pradaxa (dabigatran) from Boehringer Ingelheim and Daiichi Sankyo's new entrant Savaysa
Portola rejection hands advantage to Boehringer's Pradaxa

It is not yet clear how long the drug may be delayed, but in the meantime Boehringer's rival NOAC Pradaxa (dabigatran) - which works by inhibiting thrombin - remains the only new

More from news
Approximately 9 fully matching, plus 70 partially matching documents found.

Interview: Allan Hillgrove, Boehringer

American College of Cardiology (ACC) to educate cardiologists in China about stroke prevention in atrial fibrillation (AF) – a condition for which Boehringer markets Pradaxa (dabigatran).
Modern anticoagulants threaten status quo

Between March 2011 and February 2012, dabigatran etexilate sales crossed the 'blockbuster' $1bn threshold. ... Interestingly, a study published in Stroke in March 2012 found that dabigatran etexilate was a cost-effective alternative to warfarin.